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ANALYSIS OF ECHOCARDIOGRAPHIC FINDINGS 
IN HIV POSITIVE PATIENTS WITH CARDIAC 
SYMPTOMS 
KEY WORDS:  
• HIV,PERICARDIAL EFFUSION 
• MYOCARDITIS,PULMONARY HYPERTENSION 
 
INSTITUTION: Govt. Stanley Medical College & Hospital, Chennai 
 
BACKGROUND: Cardiac abnormalities are common in HIV positive 
patients. There is less documentation about its presentation. 
 
AIM OF THE STUDY: To describe the pattern of cardiac abnormalities in 
HIV patients. 
 
PATIENTS & METHODS: This was a hospital-based cross-sectional 
observational study. HIV positive patients, HIV patients on HARRT without 
cardiac, diabetic, hypertensive, renal and respiratory disease were selected 
for the study. They were subjected to routine investigations and then for 
Electrocardiogram, Chest x ray and Echocardiogram.  
The results were analyzed and presented here. 
 
ECHO Diagnosis Males Percentage Females Percentage 
CAD 3 3 0 0 
Cor pulmonale 5 5 1 5 
Myocarditis 9 9 1 5 
Pericardial effusion 4 4 2 10 
Systolic Dysfunction 4 4 2 10 
Diastolic Dysfunction 4 4 2 10 
Normal 66 69 13 62 
TOTAL 95 100 21 100 
 
• 32% of the patients were confirmed with cardiac disease. 
• 45.5% of the patients had CD4 count less than 200. 
• 91% were on Anti Retroviral Therapy. 
• 53.5% of the patients were in the WHO HIV clinical stage 3. 
• Most common echocardiography diagnosis was myocarditis, 
pericardial effusion, systolic dysfunction and diastolic dysfunction 
each at 7% respectively. 
• Smoking status correlated with HIV and coronary artery disease 
• Low CD4 count correlated with HIV and myocarditis. 
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INTRODUCTION 
Acquired  immunodeficiency  syndrome  is  caused   by                                
human immunodeficiency virus   which  belongs  to   class  of  
retroviridiae. AIDS   has   become    the    most  dangerous    pandemic   
which  has   plagued us    in    the   last  two   decades.  AIDS   affects   
almost  all   systems   in   our body.  
Due   to    increased   discovery    of   new   anti retroviral drugs    
against        HIV  the   survival of the patients has considerably increased 
and hence the cardiovascular complications of AIDS is of more prevalent 
now1. 
 The cardiovascular complications of HIV can be directly due to the 
virus itself, due to the associated risk factors like smoking and 
hyperlipidemias associated in HIV patients or due to the adverse effect the 
antiretroviral therapy. 
 Earlier heart diseases in HIV patients were mostly found in autopsy 
series. But with development of new diagnostic methods it is now possible 
to diagnose the cardiovascular complications of HIV in patients at a earlier 
time. 
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 Of the diagnostic modalities for early detection of cardiovascular 
complications a simple but still a very effective tool is cardiac 
echocardiography.  
The spectrum of cardiovascular conditions which can be diagnosed 
using imaging modalities include the following which are discussed in 
detail in later stage2,3  
1. Pericarditis  
2. Pericardial effusion 
3. Endocarditis 
4. Myocarditis 
5. AIDS related malignancy like Kaposi sarcoma and lymphomas 
6. Pulmonary hypertension 
7. Cardiomyopathy 
8. Coronary vascular diseases 
9. Thrombosis, embolism, vasculitis and aneurysms. 
 
Thus  its  now   important   to    screen    regularly    for                                    
cardiac complications   in     HIV patients    to    Initiate   early treatment         
and   thus   further   improving   the   survival rate   and     increase  the         
quality of life of HIV patients4. 
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OBJECTIVE 
1.  TO STUDY PATTERN OF CARDIAC INVOLVEMENT IN HIV  
            PATIENTS 
2. TO  KNOW  INCIDENCE OF VARIOUS CARDIAC DISEASES 
IN OUR POPULATION 
3. TO COMPARE RESULTS WITH AVAILABLE LITERATURE 
           MATERIALS AND METHODS 
• PLACE OF STUDY: 
           DEPARMENT OF MEDICINE, ART CLINIC, 
           STANLEY MEDICAL COLLEGE HOSPITAL 
• DURATION 
             FEBRUARY 2013 TO JULY 2013 
• STUDY DESIGN 
CROSS SECTIONAL STUDY 
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• PATIENT SELECTION: 
          HIV POSITIVE PATIENTS  
          HIV  PATIENTS ON  HAART. 
• EXCLUSION CRITERIA: 
1. KNOWN  CORONARY ARTERY DISEASE PATIENTS  
AND OTHER KNOWN HEART DISEASE PATIENTS WITH 
HIV, 
      2. KNOWN HYPERTENSIVE AND DIABETIC PATIENTS 
      3. KNOWN COPD PATIENTS 
      4. RENAL FAILURE 
• SAMPLE SIZE 
117 patients are studied . 
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METHODOLOGY 
      Patients from ART CLINIC, Medical ward in Stanley hospital from     
February to  July  2013  who are positive for HIV antibodies were included 
in the study. 
After getting informed consent from the patient, history and clinical   
examination was obtained from the patient followed by investigations.  
Apart from all routine investigations like complete blood count, 
renal function test,  lipid profile, liver function test, ultrasonogram of 
abdomen, chest x ray ,electrocardiogram,   
Echocardiography was done for all these patients and analysis was 
done from the information from all the above.   
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REVIEW OF LITERATURE 
From   the  time  HIV was recognised as a potential global health 
problem with the capacity to transform into a major epidemic affecting 
millions of people globally spreading through all countries. 
It was recognised that it could affect the heart and cause 
abnormalities in the heart. In the early times this was found by doing 
autopsy. The occurrence of heart abnormalities in HIV patients earlier was 
thought to be less. 
Later   with   the   advent   of   new  scientific   discoveries      and  
development   in   imaging  and   diagnosing   modalities  it became more 
evident that HIV affects the heart.  
And   with   the   advent   of    echocardiography   it   became  more   
apparent that  HIV   affected   the   heart  more   often and more early than 
it was earlier believed to be. 
In most of the patients the cardiac complications due to HIV is not 
apparent and the patient might not have symptoms and clinical and 
physical examination of the patient may not yield significant results but it 
might cause complications like  pericardial effusion and myocarditis which 
might have a grave consequence and might even result in death.  
7 
 
The common cardiac complications due to HIV are pericardial 
effusion and myocarditis and less common complications are 
cardiomyopathy, endocarditis and coronary artery disease5,6. 
          With the advent of anti retroviral therapy and increased awareness 
about HIV, treated patients were having much longer life than before.  
Since due to this enhanced longevity chronic cardiac ailments which affect 
normal population affects HIV patient too.  
Hence  there  is  increasing   incidence  of   coronary heart disease                    
among HIV patients.  
As a physician it is our duty to be aware of the cardiac 
complications of HIV in our patients and anticipate them and take 
adequate measures to prevent development of risk factors,  prevent 
progression of disease and finally to treat the cardiac ailment and try to 
prevent the complications and reducing the morbidity and mortality due to 
the disease7,8,9. 
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STRUCTURE OF HUMAN IMMUNODEFICIENCY  
VIRUS 
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LIFE CYCLE OF HUMAN IMMUNODEFICIENCY  
VIRUS 
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STAGES OF REPLICATION 
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RISK FACTORS FOR CARDIAC DISEASE IN  
HIV PATIENTS 
1) DYSLIPIDEMIA  
 Often HIV  infected   patients  suffer  from   dyslipidemias.  
Their  LDL , total cholesterol  and  triglycerides  are  often  high  
and  the level of HDL which is a good cholesterol serving as a scavenger 
of bad cholesterol is often low.  
More over HIV patients average life span has increased  
considerably in recent  times due  to  advances  in  medical science. 
As a result of this HIV patients are increased risk of plaque 
formation in the coronaries and their chance of having a cardiac event is 
more high now than ever. 
 
2) SMOKING 
About   two third   of  the   HIV infected patients   are   found   to  be         
smokers. Smoking   is   an    independent   risk   factor  for    coronary   
vascular  event. 
Smoking  synchronises the risk of coronary vascular event with HIV 
infection. 
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3) CHRONIC INFLAMMATION 
Its   now   believed  that  in   HIV  the  arteries  and  veins  are  
involved  and are in a state of chronic inflammation.  
As   a  result  there  is   increased chance of  plaque  formation  in                           
the inflamed arteries and increased chance of myocardial vascular 
insufficiency. 
4) DIABETES 
Diabetic  patients   often  suffer  from   dyslipidemias  and  
macrovascular involvement  in  diabetes  is  often  the  major  cause  of    
silent myocardial infarction. Hence HIV patients with diabetes have an 
increased risk of adverse cardiac events. 
5) CHRONIC KIDNEY DISEASE 
 HIV often affects the kidneys and is one of the important cause of 
focal segmental glomerulosclerois. Damage to the kidney might have an 
adverse effect on the blood pressure which in turn will affect the heart by 
increasing the afterload putting more strain on the heart. And when the 
kidney function deteriorates a volume overload state occurs increasing the 
preload thereby compounding the strain on the heart 
 
13 
 
PERICARDITIS AND PERICARDIAL EFFUSION 
Pericardial effusion   has   an   incidence   rate   of  eleven percent in 
the time before the anti retroviral therapy was in use.  
Pericardial effusion is one of the most common cardiac 
complications in HIV infected patients. Prevalence of pericardial effusion 
is higher among HIV patients when compared with that of non HIV 
patients10,11. 
Stage  of  HIV correlate with severity of effusion. 
Most of effusions detected are smaller effusions and most of them 
are asymptomatic. 
When HIV reaches end stage malignancies are found to be 
associated with pericardial effusions and also infections13. 
Pericarditis may lead to pericardial effusion which may result in 
cardiac tamponade causing diminished heart sounds , raised jugular venous 
pressure and hypotension. 
 It is so common that patients with pericardial effusion should be 
screened for HIV infection. 
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If pericardial effusion occurs in HIV patients it indicates grave 
prognosis and the chances of survival is very dim irrespective of the CD4 
count. 
The median age of survival of HIV patient with pericardial effusion 
was found to be 6 months. 
However it is still unclear whether HIV is the direct cause of 
pericardial effusion.14,15 
 
ETIOLOGY 
In most cases the cause of pericardial effusion couldn’t be ascertained. 
But many organisms have been found to be associated with pericardial 
effusion in HIV infected patients. Many of them are co infection and many 
are due to opportunistic  organism which predominantly affect immune 
compromised individuals. They are 
 Mycobacterium tuberculosis 
 Mycobacterium avium complex 
 Nocardia asteroids 
 Chlamydia  
 Staph aureus 
 Listeria monocytogenes 
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 Rhodococcus 
 Coxsackie 
 Ebstein barr 
 Herpes simplex 
 Adenovirus 
 Cytomegalovirus 
 Toxoplasma gondii 
 Histoplasma 
 Cryptococcus 
 
Other than infections, Neoplastic etiology includes, neoplasms like 
Kaposi sarcoma, lymphoma. Non infectious etiology includes, 
malnutrition, acute myocardial infarction, cirrhosis, uraemia, 
hypothyroidism connective tissue diseases, drugs, toxins, trauma and 
radiation are also found to be  associated with the development of 
pericardial effusion in HIV patients16. 
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CLINICAL FEATURES 
In many patients pericardial effusion might remain quiescent 
without any signs and symptoms. The earliest signs may be cough , chest 
pain and increase in temperature. 
 However in some patients the course may be severe and it might 
present with severe hypotension , shock and cardiac arrest. 
 Sometime even at lower volume some HIV patients  may go for 
shock which seen in thin cachectic patients .Mechanism behind this ‘low 
volume tamponade’ is when the patient is severely dehydrated , there is 
severe volume loss and hence there is reduced right ventricular inflow and 
hence reduced filling pressure of right ventricle, in such a picture even 
mild pericardial effusion can precipitate tamponade17,18.  
In some patients there is spontaneous resorption of pericardial fluid. 
However the prognosis in HIV patients who develop pericardial effusion 
with or without symptom is poor with increased mortality within 6 months.  
Thus pericardial effusion is a marker for advanced disease and poor 
prognosis in HIV patients19. 
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Below is chest x ray  of pericardial effusion(gross enlargement of 
cardiac borders to pericardial effusion) 
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DIAGNOSIS 
Electrocardiography shows low voltage complexes, electrical 
alternans, T wave inversion and p wave changes, 
Shown below was ECG of pericardial effusion showing electrical 
alternans and low voltage complexes 
 
Echocardiography  is  the   most   easy   and   reliable   way  to 
detect pericardial effusion. 
 Pericardial effusion is diagnosed when the space between parietal 
and visceral pericardium gets persisted throughout the cardiac cycle during 
recording. 
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The characteristic findings found in echo for moderate to severe 
effusions are compression of the right atrium and the collapse of the right 
ventricle during diastole.   
In order to find the etiology, pericardiocentesis can be performed 
and the sample can be sent for culture , polymerase chain reaction test,  
immuno fluorescent test and other tests to find out the etiological agent20.  
 
Below is echo image of pericardial effusion 
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MANAGEMENT 
Institution of highly active anti retroviral therapy results in reducing 
the viral load and reducing the immuno compromised level thereby 
decreasing the chance of occurrence of opportunistic infections and 
 thus has been found to delay the onset of pericardial effusion in HIV 
infected patients. 
NSAID’s can be given which provides some relief. 
Initial evaluation always centers around to see for all causes other 
than HIV 
Which  includes  etiologies  mentioned  above.  
Attention should be paid especially to curable conditions like  
tuberculosis, also every attempt should be made should be made to find 
etiological diagnosis.  
Pericardiocentesis  can done as diagnostic  procedure and pericardial 
fluid can be sent for analysis, that includes biochemical,microbiological 
and pathological analysis. 
 For  those  patients   who   come  in  state  of  pericardial tamponade         
showing signs of 
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“Becks Triad”(distant heart sounds,distended neck veins,low blood 
pressure” 
patient  should  be  hospitalised  and  urgent  pericardiocentesis                        
should  be   done. 
Pericardiectomy can be done for patients with recurrent effusions as 
in the case of neoplastic and other chronic pericarditis21-24. 
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ENDOCARDITIS 
Endocarditis   is    inflammation   of   lining  of    heart valves    
which  is often caused by infection.  
People who develop the condition have already existing heart 
problems and are over 50 years old, but can occur at any age, including 
children. 
 While not common, this can be a serious disease. Men are twice 
likely to be affected as women. 
TYPES: 
There are two types of endocarditis: infective & non-infective. 
 With effective  treatment, the majority of people with infective 
endocarditis will survive. Non-infective endocarditis is  difficult to treat. 
Both thrombotic endocarditis due to non bacterial cause as well as 
infective endocarditis has been reported in HIV infected patients.  
HIV patients who are intravenous drug abusers are at highest risk of 
developing endocarditis. Right sided valves are mostly involved in HIV 
patients who are drug abusers. The mortality is more in patients with 
advanced disease25.  
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CAUSES OF ENDOCARDITIS 
The most common organism is staphylococcus aureus followed by 
streptococcus viridans. The other organisms causing endocarditis are   
 Staphylococcus epidermis, 
 Haemophilus influenza, 
 Streptococcus pneumonia  
 HACEK group of organisms, 
 Salmonella, 
 Mycobacterium avium complex,  
 Methicillin resistant staphylococcus aures 
 Fungi like candida,  aspergillus, Cryptococcus.  
Following conditions elevate the risk both in HIV and  
non HIV patients: 
 A history of rheumatic fever/rheumatic heart disease 
 A congenital  heart defect 
 Prosthetic heart valves 
 History of intravenous drug use 
 Mitral valve prolapse (MVP) 
 Diabetes 
 Pregnancy 
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 Endocarditis develops in endocardium, the inner tissue of heart.  
It starts if this tissue has been damaged, injured, or infected.Just as a 
cut on the skin causes a scab , damage to the endocardium leads to 
formation of  blood and tissue clot (thrombus). 
In infective endocarditis, the clots may be caused by HIV infection, 
inflaming and damaging the heart cells. 
SYMPTOMS  
The symptoms of endocarditis can be  similar to routine infective 
endocarditis picture and infact it is more  and may include: 
 high temperature (fever)  above 38C (101.4F) 
 chills 
  headache, 
 joint pain  and   
 muscle pain 
 A new or changed heart murmur - not normal heart sounds  made  
by blood rushing   through  heart, 
• Fatigue, Joint and  muscle aches, 
• Night sweats, 
• Shortness of breath , 
• Paleness, Persistent cough, 
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• Swelling of feet, legs or abdomen, 
• Unexplained weight loss, 
• Blood in urine (either visible or found in a doctor's viewing of 
your urine under a microscope)(hematuria), 
In patients with HIV wasting syndrome, marantic endocarditis can 
occur which mainly affects left sided valves and it consist of friable 
vegetations composed of platelets, inflammatory cells encompassed within 
a mesh made up  of fibrin.  
Systemic embolization from this vegetation is a rare cause of death 
in HIV patients. 
TESTS AND DIAGNOSIS : 
Blood Tests: 
 Blood culture  to identify bacteria in  blood. Blood  tests  helps  
doctor identify  conditions, including anaemia. 
Transesophageal echocardiogram:  
An echocardiogram use sound waves to produce image of heart at 
work. The echocardiogram allow doctor to get closer look at valves. 
 
 Computerized tomography (CT) scan and magnetic resonance 
imaging (MRI): 
There may be a need for CT or MRI  of  brain, ch
of your body if  doctor thinks the infection has spread 
Vegetation on the atrial side of anterior leaflet of mitral valve due to 
candida in hiv positive patient
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TREATMENT 
Apart from ART drugs antibiotics have to be added in the treatment 
of HIV associated endocarditis. 
There is a need for high doses of intravenous  antibiotics in  hospital. 
Blood cultures help  to identify  type of microbes that is infecting the heart. 
 This information will help to choose the best antibiotic or 
combination  to fight the infection. 
 
Surgery 
 
         If  infection damages heart valves, we  may have symptoms and 
complications years after treatment.  
Occasionally  surgery is required to treat persistent infections or 
replace a damaged valve. 
 Surgery is sometimes needed to treat endocarditis that is caused by  
fungal infection. 
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MYOCARDIAL INVOLVEMENT 
Myocarditis is defined as inflammation of myocardium having wide 
variety of presentations.HIV virus is been found out to be  one of the 
prominent causes of dilated cardiomyopathy. 
 
Pathogenesis of myocarditis in HIV shares multiple mechanics 
Damage occurs through the following ways: 
 Direct effects of causative agent 
 Secondary immune response,which is  triggered by  causative 
agent 
 Cytokine expression of  myocardium ( tumor necrosis factor 
[TNF]  alpha, nitric oxide synthase) 
 Aberrant induction of apoptosis, 
Myocardial damage consists of  2 main phases: 
 Acute phase (first 2 wk)  
Myocyte destruction as a direct consequence of offending agent. 
 Chronic phase (>2 wk)  
Continued myocyte destruction is of  autoimmune nature, with 
associated different expression of human leukocyte antigen (HLA) 
in the myocytes. 
 
29 
 
Histological section of HIV :   
Consisted of multifocal or interstitial inclusions of small 
lymphocytes and isolated myocyte necrosis. 
 The lymphocytes that are seen includes T cells (CD2+, CD3+)   and   
some cells that are not identified by the usual markers. Rarely B cells, 
monocytes, CD4+ cells, and natural killer (NK) cells were seen in the 
section. 
The  prognosis  in  patients  who  have   dilated cardiomyopathy                       
due  to  HIV  is  very  poor26-30. 
  
 
HISTOLOGICAL APPEARANCE 
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Moreover   the  use   of zidovudine has been found to be associated 
with mitochondrial myopathy.  
Studies have shown that zidovudine causes destruction of 
ultrastructures of the mitochondria with inhibition of replication of 
mitochondrial DNA. 
 Patients with myocarditis  can have a history of acute 
decompensation of heart failure, but may or may not  have  other cardiac 
dysfunction or have decreased cardiac risk.  
The diagnosis is  presumptive, relies on patient demographics and 
clinical course. 
Patients present with mild symptoms of angina ( concurrent 
pericarditis), fever, sweating, chills, and difficulty in breathing. 
In viral myocarditis, patients present with  history of recent (within 
1-2 wk) flu like syndrome of  fever, arthralgias , and malaise and 
pharyngitis, tonsillitis, or upper respiratory tract disease. 
Patients with myocarditis present with, signs and symptoms of 
decompensation or heart failure (eg,tachycardia, gallop, mitral 
regurgitation, swelling of legs) and, in those with concomitant pericarditis, 
with pericardial friction rub. 
When myocarditis is severe,  it  permanently damages  heart muscle,  
this  may  result  in 
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 Heart failure: 
 If  left untreated, myocarditis  damages  heart's muscle to a point it 
can no longer pump blood effectively, causing heart failure.  
 Heart attack or stroke:  
If  heart's muscle is injured and cannot pump blood, the blood that 
pools in  heart  forms clots. If a clot blocks one of the heart's arteries, it can 
cause a heart attack. If a blood clot in the heart travels to artery it leads to a 
stroke. 
 Arrhythmias: 
 Damage to  heart muscle  causes disturbance in heartbeat regularity 
 Sudden death: 
   If  heart muscle is so damaged, it is possible the arrhythmia could 
cause the heart to suddenly stop beating (sudden cardiac arrest). 
Diagnosis can be made out by using 
 Electrocardiography, 
 Echocardiography, 
 Nuclear imaging, 
 Nardiac magnetic resonance imaging and  
 Endomyocardial biopsy. 
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ECG of  acute myocarditis usually shows  
 ST elevation without reciprocal ST depression was one of  the 
characteristic finding  during  acute stage. Total QRS amplitudes in acute 
stage was  low voltaged when compared to those QRS complexes before 
illness. 
 Above two finding helps us to differentiate from  myocardial 
infarction. 
Also diffuse T wave inversion can occur in these patients along  
with saddle shaped ST elevation. 
 Abnormal Q can occur if present,  the leads showing Q waves are  
inversely with  left ventricular (LV) ejection fraction30,31. 
 
ECG OF MYOCARDITIS showing diffuse T wave changes 
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TREATMENT 
It is similar to routine management as managing a cardiac failure 
patient If myocarditis  causes heart failure or rapid or irregular heartbeat, 
hospitalisation is required.Drugs for regulating heart beat may be required. 
If  heart is weak, doctor may prescribe medications to reduce  heart's 
workload or help  eliminate excess fluid.  
These medications include: 
 Angiotensin-converting enzyme (ACE) inhibitors: 
 That relax the blood vessels in heart and help blood flow more easily. 
 
 Angiotensin II receptor blockers (ARBs): 
 That relax the blood vessels in  heart and help blood flow more easily 
 
 Beta blockers:  
Work in multiple ways to treat heart failure and help control irregular 
heart rate 
 
 Diuretics:  
Such as furosemide (Lasix), that relieve sodium and fluid retention 
 
34 
 
Treating severe cases: 
In some severe cases of myocarditis, aggressive treatment is 
necessary, such as: 
• Intravenous (IV) medications: 
 IV delivery of medications  improves the heart-pump function 
quickly. 
• A pump in the aorta (intra-aortic balloon pump):  
In this a balloon is surgically inserted into aorta. As  balloon inflates 
and deflates, it helps  increase blood flow and decrease workload on heart. 
• Increasing the oxygen content of the blood (extracorporeal membrane 
oxygenation, or ECMO): 
 With severe heart failure, doctors sometimes recommend use of 
device to provide oxygen to the body. When blood is removed from body, 
it passes through  ECMO machine which removes carbon dioxide and adds 
oxygen to  blood. The newly oxygenated blood is  returned to  body. 
The ECMO machine takes over the work of the heart. 
This treatment is used to allow the heart recover or to wait for other 
treatments.. 
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Other management options include surgical techniques like  
 Left ventricular reconstruction and  
 Implantation of external restraint devices. 
 Emerging specific techniques include agents to eradicate 
persistent viral infections and  
 Immunomodulatory agents . 
 Stem cells for cardiac regeneration and  
 Gene therapy are in the pipeline32-34. 
 
Echo image of dilated cardiomyopathy due to myocarditis 
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AIDS RELATED MALIGNANCY 
Malignancy is a known complication of immunodeficiency caused 
by HIV. Mechanism through which these malignancies occur varies among 
each of the tumours and types. 
Tumours commonly seen with HIV include 
 Hodgkins disease , 
 Non Hodgkins lymphoma, 
 Kaposi sarcoma, 
 squamous cell neoplasia, 
 plasmacytoma38. 
Some secondary virus associated AIDS malignancies include 
Ebstein-Barr virus (EBV) related  Non-Hodgkin’s lymphoma ,PCNS 
lymphoma, some systematic and oropharyngeal (T-cell) malignancies, 
Hodgkin’s disease. 
Human papillomavirus (HPV) associated Squamous cell neoplasia 
and other Non-AIDS defining cancers. 
KS can occur  in three different forms,  
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 Classic KS, described by Moritz Kaposi, is seen as plaques or 
nodules  on the feet and hands, rarely enters the Viscera.It is seen 
in males age more than 70 years.  
 
 Endemic KS, is similar to classic  KS  in  its  male  pattern  but 
differs in that it shows a bimodal age distribution, a larger group 
occurring at the age of 30 to 50 years, and a lesser group occurring 
at 5 to 10 years. 
 
Clinically, these lesions are seen on the feet and in the hands, as 
plaques and enlarge to form nodules that can join to form florid lesions 
 
This type of sarcoma occurs in the heart. 
 
Histologically, all  forms of KS appear as the same, seen as vascular 
clefts and spindle cells(these are the suspected tumor cells). 
 
 KS acts as an inflammatory lesion in the earlier stages, with    more    
vascular     reaction     and less amount of spindle cells. But the volume of  
spindle cell increases as the lesions begins to  mature. 
 
No typical or regular chromosomal or genetic pattern was in the KS 
spindle cells, and it is not found that KS is formed from a single clone or 
multiple clones. 
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Endemic Kaposi sarcoma of heart mostly involves the pericardium 
both visceral and parietal and in rare cases involves the myocardium , 
endocardium and coronary vessels. 
 
Cardiac Kaposi sarcoma in HIV patients usually remains occult and 
often not diagnosed during the life time.  
 
The involvement of Kaposi sarcoma in the pericardium usually does 
not affect the functioning of the heart but in rare cases it might lead to 
cardiac tamponade and constrictive pericarditis39-42.  
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MECHANISM TO EXPLAIN PATHOGENESIS 
 
 
Even though direct lymphomas of the heart are rare, lymphomatous 
infiltration of the heart might occur due to metastasis from the extranodal 
sites eg. may be a result of contagious spread from a mediastianal mass. 
These are are derived from immunoblastic cells of B type or from burkitts.  
 
The involvement can be a small isolated region or diffuse. 
  
In recent times the occurrence of Kaposi sarcoma and non hodgkins 
lymphomas have dwindled down because of introduction of HAART. 
 
The immunologic status of the patients is now better and hence the 
reason for lesser incidence of these complications
 
Sectioning of Kaposi sarcoma showing increased vascularity
intracellular hyaline globs and many spindle cells
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PULMONARY HYPERTENSION 
         Lung is one of the frequent target for HIV.The prevalence of HIV 
related pulmonary hypertension(HRPAH) is about 0.5%. 
 
         Association between viral load and CD4 count with HRPAH was 
not proved significantly in statistics,but pulmonary hypertension is severe 
in HIV patients. 
 
         Histological examination of HRPAH and idiopathic PAH are not
different. 
 
         Pulmonary vasculature is obliterated due to  medial hypertrophy and 
increased proliferation of endothelial and smooth muscle cells. 
 
        Proposed mechanism is due chronic infection by hiv results in 
immune action and subsequent release of proinflammatory cytokines and 
release of growth factors during later stages. Also subcellular membrane 
disruption occurs in endothelial cells and smooth muscle cells. 
 
         Histology of frequently found plexiform lesions in vessels showed 
endothelial cells with enlarged endoplasmic reticulum,golgi stacks,
vacuolation. 
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         Viral proteins are implicated in all the above mentioned pulmonary 
vascular damage which includes envelope protein 120(env), hiv 
negative(nef) factor protein and transcriptor activation protein 
(tat).Envelope protein attaches to endothelium of vessels as they are vital 
for attachment of hiv to endothelium and apart from damaging 
endothelium they activate macrophage and monocyte to release 
proinflammatory cytokines. Tat and Nef are antigenic and they damage 
resting T cells48-49. 
 
Above picture shows proposed mechanism of HRPAH. 
        Triangled area are places which need further research work. 
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ECG manifestation includes typically rightsided atrial enlargement, 
right ventricle enlargement, axis deviation to right and often an associated 
right bundle branch block. Echo reveals the presence of right atrial and 
right ventricular enlargement.  
ECG of pulmonary hypertension showing Complete Right bundle 
branch block with secondary changes 
 
 
 
By using Doppler studies we can measure the regurgitant flow over 
the tricuspid valves with which we can estimate systolic right ventricular 
and  systolic pulmonary artery pressure.  
The most accurate measurements of pulmonary and intracardiac 
pressures can be made with catheterisation of the right sided heart. 
 
  Management includes vasodilators like calcium channel blockers, 
prostacyclin analogue like epoprostenol.
 
 Use of betaprostane orally active prostacyclin is also being 
studied50-52. 
 
Chest posteroanterior and latera
HIV test result demonstrate clear lungs with prominent hila and dilated 
pulmonary arteries. These findings are consistent with a diagnosis of 
pulmonary hypertension
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l film in a patient with a positive 
 
.     
  
 
D-sign (left image) and dilated main pulmonary
artery (right image) in a patient with pulmonary hypertension
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EVALUATION OF PAH 
 
  
47 
 
 
HIV WITH CORONARY ARTERY DISEASE AND 
ATHEROSCLEROSIS 
 
With the advent of HAART the progression of HIV infection has 
slowed down and the patients are living for a longer period of time. As a 
result of increased life expectancy of the HIV patients now these patients 
are more prone to risk factors as a normal population for cardiovascular 
diseases.  
 
At the same time HIV infection by itself is a separate independent 
risk factor for development of cardiovascular diseases. Moreover HAART 
especially protease inhibitors induced dyslipidemias and glucose 
intolerance which further increases the risk of atherosclerosis. Studies have 
found that HIV patients with coronary vascular disease develop 
myocardial infarction a decade earlier than the normal population and are 
more often smokers with deranged lipid profile. Thrombolysis in 
myocardial infarction score is lower in HIV patients .HIV infected patients 
have higher chance of restenosis than normal population. 
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HIV AND HYPERTENSION 
Due to reduction in morbidity of HIV patients due to HAART long 
term adverse effects like dyslipidemia, altered glucose levels, 
lipodystrophy, and other metabolic complications are on the rise. There are 
important concerns about premature cardiovascular disease and the role of 
HAART in its development. 
 
As hypertension is an important risk factor for cardiovascular 
disease, understanding the  association between HAART and hypertension 
is vital. 
 
Factors  that are associated with hypertension  include increasing 
age,long duration of the disease, diabetes, and elevated BMI and other 
traditional risk factors. 
 
HIV infection was found to cause arterial stiffness and 
proinflammatory responses which leads to pre-mature vascular dysfunction 
causing elevated blood pressure. Besides endothelial dysfunction and 
accelerated vascular aging, subclinical HIV-associated kidney effects that 
occurs in HIV can also explain the high rates of hypertension among HIV 
patients 
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  The occurrence of hypertension in HIV patients has been linked to 
metabolic syndrome and insulin resistance occurring in HIV patients. 
Some studies indicate that protease inhibitors or NNRTI in the occurrence 
of hypertension in HIV patients. Smoking is more associated with HIV 
patients which increases the occurrence of elevated blood pressure53-57. 
 
ECHO FEATURE OF SEVERE LVH 
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ECHO IMAGE OF NORMAL HEART AND LVH 
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HIV AND DIABETES 
HIV patients are frequently seen with diabetes and metabolic 
complications. 
Three groups of patients with diabetes and HIV are identified:  
Those with preexisting diabetes who contract HIV, those who are 
found to have diabetes at onset of HIV infection, and others who develop 
hyperglycemia after start of therapy for HIV. Each subgroups has to be 
managed differently, because the mechanisms of metabolic dysregulation 
vary in each of the categories. Traditional risk factors play role also in the 
development of metabolic complications especially high body mass index, 
greater waist circumference or waist- to-hip ratio, lower socio economic 
status, and some ethnic backgrounds and culture added with high viral 
load, low  CD4 count. 
Altered glucose tolerance, and insulin resistance usually precede 
weight loss in  HIVpatients. 
Insulin resistance, rather than insulin deficiency, is usually the cause 
in the pathogenesis of diabetes in HIV-infected patients. Earlier reports ,of 
islet cell autoimmunity, or beta cell destruction has not been seen in HIV 
patients. 
But autoimmune diabetes has been reported to develop in some 
HIV-infected patients after immune recovery during HAART therapy, 
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which is type one DM, and the antibody detected was glutamic acid 
decarboxylase. But majority of patients of were  type2 DM. 
Studied mechanism implicated in insulin resistance in HIV patients 
include  
1) Endocrine abnormally especially growth hormone resistance, 
2) Due to  wasting of subcutaneous fat, there occurs visceral 
accumulation of fat   in these patients, which creates increase in the levels 
of inflammatory cytokines such as TNFa. 
3) HIV-infected patients with metabolic syndrome show alterations 
in inflammation and adipokines 
4) Concurrent association of Hepatitis c virus which increases the 
risk  due intrahepatic steatosis and intra heatic necrosis.patients above the 
age of 40 years are 3 times more at risk of getting diabetes 
5) Drugs – PI drugs  increase insulin resistance and reduce insulin 
secretion, by altering GLUT-4 mediated  transport of molecules of glucose.  
 PIs interfere with the cellular retinoic acid-binding protein type 1 
(CRABP 1) that combines with the peroxisomal proliferator-activated 
receptor (PPAR). Inhibition of this PPAR causes adipocyte inflammation, 
and  release free fatty acids and hence insulin resistance. This altered 
glycemic profile resolves in most patients when PI drugs are discontinued. 
Metabolic effects vary among each PI. 
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Indinavir  causes insulin resistance with no effect on lipid 
metabolism, but lopinavir and ritonavir cause increase in the fasting 
triglycerides and free fatty acids levels, but do not alter the insulin 
sensitivity. 
 Indinavir and ritonavir inhibits GLUT -4 receptors, HIV patients 
treated for 3 months with nelfinavir, indinavir, liponavir or saquinavir, 
show  alterations in first phase insulin release with a one fourth reduction 
in beta cell function. 
This shows  that  there is no group  effect of PIs on diabetic and its 
profile and that each of the PIs must be studied individually, When their  
metabolic effects are considered. 
The treatment implication is that treating doctor must know 
predominant mechanism of diabetes due to each of the drugs given, only 
then proper antidiabetic treatment can be given. 
NRTI’s especially zidovudine,stavudine,didanosine are associated 
with insulin resistance by causing mitochondrial dysfunction, 
lipodystrophy. 
Drugs like pentamidine, a drug used for treatment of pneumocystis 
carinii infection in HIV is associated with rise glucose status. so it is 
important to know about other drugs used in HI58-60. 
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Treatment of Coronary Risk Factors in HIV Patients 
The primary treated strategy involves tackling the metabolic 
syndrome associated with HIV infection. Weight loss , exercise, smoking 
cessation and correcting dyslipidemias are the cornerstone in treatment of 
risk factors of coronary heart disease in HIV patients 
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WEIGHT LOSS 
If the body weight of the patients is reduced moderately it will lead 
to drastic improvement in lipid profile, hypertension, and diabetes, 
inflammatory and thrombotic markers. 
 
SMOKING CESSATION 
Studies reveal that about two third of the HIV patients are smokers. 
Smoking cessation must be a prime focus  in the  care of HIV patients who 
are smokers. 
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HIV AND HYPERLIPIDEMIA 
Hyperlipidemia in HIV patients is due to increase in very low 
density lipoprotein and intermediate density lipoproteins. This altered lipid 
profile is common patients on antiretroviral therapy, particularly with 
protease inhibitors and stavudine,it can also occur during long duration the 
disease per se. Guidelines given by National Cholesterol Education 
Program (NCEP) cannot be implemented completely to HIV- patients. 
Mechanism of hyperlipidemia due to these drugs was thought to be due to 
reduction in the clearance of VLDL and triglyceride remnants,or an insulin 
resistance which causes sequestration of free fatty acids adipose tissue due 
resistance occurring there, with resulting increased VLDL – TGL 
production.Hence these patients are at increased risk of adverse 
cardiovascular events.  
 
These patients are refractory to routine pharmacotherapy due to 
above mechanism and NCEP's recommendation has to be modified. A 
patient's cardiac risk should first be assessed. Measures like low-fat diet, 
weight reduction, and exercise, must be instituted early. Drug treatment is 
recommended for patients with familial combined hyperlipidemia, for 
patients with triglyceride values more than 1000 mg/dL. Drugs used are 
niacin and statins, fibric acid derivatives and probucol. Any drug change 
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among antiretroviral drugs, that has suspected to be causing hyperlidemia 
should be carefully done as it can result in dangerous virus rebound and 
disease progression. NCEP guidelines advise monitoring low-density-
lipoprotein cholesterol levels four to six weeks after starting lipid lowering 
therapy and then at three months in HIV negative patients; more frequent 
assay has to be done in HIV-infected patients62-64.  
 
 
  
Gender 
Number 
Percentage 
 
82% of the patents were males and 18% were females.
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RESULTS 
 
Gender 
Male Female 
95 21 
82 18 
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Total 
116 
100 
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 Age Group male
30-40 
41-50 
51-60 
61-70 
Total 
 
Age 
N 
Mean 
SD 
P value 
Unpaired t test 
 
In our study majority of the 
and only 17% of the males and no females above 50 years of age.
conventional criteria age difference between males and females is 
considered to be not statistically significant since p > 0.05.this establishes 
the fact that in spite of difference in the number of observations in each 
gender group, we are dealing with statistically similar groups.
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AGE 
 
 % female 
20 21.05 7 
58 61.05 14 
16 16.84 0 
1 1.05 0 
95 100 21 
male 
95 
45.20 
5.84 
0.107 
patients are in the age group 41
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% 
33.33 
66.67 
0.00 
0.00 
100 
female 
21 
41.52 
6.09 
-50 years 
By 
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 CD4 Count Male
1-200 50
201-350 18
>350 27
Total 95
Proportion 
with CD4 < 
200 (%) 
P value
Fisher's 
exact test
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CD4 COUNT 
 
 Percentage Female 
 53 8 
 19 9 
 28 4 
 100 21 
 
 
0.335 
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Percentage 
38 
43 
19 
100 
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CD4 Count Male Female 
Number of Observations 95 21 
Mean Age 271.49 271.48 
Standard Deviation 208.53 153.06 
P value 
Unpaired t test 
0.9998 
 
58(45.5%) of the patients had CD4 count less than 200, 31% had 
CD4 count between 201-350 and 23.5% had CD4 count more than 350.  
By conventional criteria the association between the gender groups 
and CD4 count is considered to be not statistically significant since p > 
0.05. Even the Proportion with CD4 < 200 is not considered to be 
statistically significant since p > 0.05.  
 PATIENTS RECEIVING ART
 
Patients 
receiving ART 
ART + 91
ART - 4
Total 95
P value  
Fisher's exact test 
0.1106
    
109 patients (91%) were on Anti Retroviral Therapy and 9% are not 
on ART. By conventional criteria the association between the gender 
groups and patients on ART is considered to be not statistically significant 
since p > 0.05. 
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Male Percentage Female
 96 18 
 4 3 
 100 21 
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 Percentage 
86 
14 
100 


 Duration of 
disease in 
years 
Male
0-1 years 14
1-2 years 40
2-3 years 33
3-4 years 
4-5 years 
Total 95
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DURATION OF DISEASE 
 Percentage Female 
 15 5 
 42 8 
 35 8 
7 7 0 
1 1 0 
 100 21 
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Percentage 
24 
38 
38 
0 
0 
100 
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Duration of Disease in years Male Female 
Number of Observations 95 21 
Mean Age 2.37 2.10 
Standard Deviation 0.86 0.82 
P value 
Unpaired t test 
0.17128 
  
Majority of the patients (40%) had the disease between 1-2 years.  
8% of the males and none of the females had the disease beyond 3 years. 
By conventional criteria the association between the gender groups and 
duration of the disease is considered to be not statistically significant since 
p > 0.05 
  
  
  
CLINICAL STAGING OF HIV
 
Clinical 
Staging of 
HIV(WHO) 
Male 
Stage 1 1 
Stage 2 3 
Stage 3 56 
Stage 4 35 
Total 95 
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 (WHO)
Percentage Female Percentage
1 0 
3 5 
59 10 
37 6 
100 21 100
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P value 
Fisher's 
exact test 
0 
0.009 
24 
48 
29 
 

 

 

 

 
66 
 
At presentation most patients were in the WHO HIV clinical stage 3 
(53.5%) followed by stage 4 (33%).By conventional criteria the 
association between the gender groups and clinical staging of HIV is 
considered to be statistically significant since p < 0.05.  
 
This indicates that there is a true difference among groups and the 
difference is significant. In simple terms male patients in our study tended 
to be in stage 3 and 4 of the clinical staging when compared to female 
patients. In respect of WHO clinical staging, 96% of HIV positive male 
subjects were in WHO Stages 3 and 4 compared to 77% of female subjects 
at the same stages. This difference is true and significant and has not 
occurred by chance.  
 
 
  
 Smoking Status 
Smoking + 78 
Smoking - 17 
Total 95 
P value 
Fisher's exact test 
0.0001
    
In our study 82% (n=78) of male subjects and 5% (n=1) of the 
female subjects had the habit of smoking. 
association between the gender groups and smoking  is considered to be 
statistically significant since p < 0.05.This indicates tha
difference among groups in reference to smoking habit and the difference 
is significant. It indicates significantly more men are smokers. This 
difference is true and has not occurred by chance.
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SMOKING 
Male Percentage Female
82 1 
18 20 
100 21 
 
     
By conventional criteria the 
t there is a true 
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 Percentage 
5 
95 
100 
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ALCOHOL 
 
Alcohol 
Intake 
Status 
Male Percentage Female Percentage 
Alcohol + 61 64 1 5 
Alcohol - 34 36 20 95 
Total 95 100 21 100 
P value 
Fisher's 
exact test 
0.0001 
 
In our study 64% (n=61) of male subjects and 5% (n=1) of the 
female subjects had the habit of consuming alcohol. By conventional 
criteria the association between the gender groups and alcohol 
consumption is considered to be statistically significant since p < 0.05.This 
indicates that there is a true difference among groups in reference to 
consuming alcohol and the difference is significant. It indicates 
significantly more men are alcohol consumers among HIV+ patients in our 
study. This difference is true and has not occurred by chance. 
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Cardiac 
Symptoms 
ofPatients 
Breathlessness 
Palpitation 
Giddiness 
Chest Pain 
Total 
 
The most common presenting cardiac symptom was chest pain 
(43.5%), while the least common was giddiness (1.5%). Breathlessness 
and palpitation were present in 28% and 26.5% of the patients, 
respectively. Multiple complaints were common and 38% of the patients 
had more than one symptom. 
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Cardiac Symptoms 
Male Percentage Female 
22 23 7 
23 24 6 
3 3 0 
47 49 8 
95 100 21 
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Percentage 
33 
29 
0 
38 
100 
'
&$
(
)#
#!$
*#++#$
,&(
#$
 ECHOCARDIOGRAPHIC DIAGNOSIS
  
ECHO Diagnosis 
CAD 
Corpulmonale 
Myocarditis 
Pericardial effusion 
Systolic Dysfunction
Diastolic  
Dysfunction 
Normal 
Total 
 
The most common echocardiographic diagnosis was myocarditis, 
pericardialeffusion, systo
7% respectively. 65.55 of the study subjects were 
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Males Percentage Females
3 3 0 
5 5 1 
9 9 1 
4 4 2 
 4 4 2 
4 4 2 
66 69 13 
95 100 21 
lic dysfunction and diastolic dysfunction, each at 
significantly normal. 
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 Percentage 
0 
5 
5 
10 
10 
10 
62 
100 
71 
 
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF ECHOCARDIOGRAPHIC DIAGNOSES 
 
CAD Corpulmonale Myocarditis 
Pericardial 
effusion 
Systolic 
Dysfunction 
Diastolic  
Dysfunction 
Normal 
N 3 6 10 6 6 6 79 
Mean (SD) age 
(years) 
46.7(4.2) 45.8(5.2) 40.8(4.3)* 39.3(6.9)* 41.3(8.9) 43.8(3.8) 45.5(5.90 
Males (%) 100 83 90 67 67 67 84 
Mean (SD) SBP 
(mmHg) 
110.7(19.7) 115(5.2)* 109.4(5.7)* 104.7(8.2) 114(8.4) 115(3.7) 120.1(9.7)* 
Mean (SD) DBP 
(mmHg) 
79.3(16.8) 77(5.3) 71.2(4.8)* 73.3(7.2) 69.7(5.1)* 71.3(5.0) 75.6(7.7)* 
Mean (SD) pulse 
rate (b/min) 
84.7(10.5) 115.7(4.6)* 116.3(5.80* 100(1.8) 88(9.2) 81.8(7.0) 81.5(7.4)* 
Mean (SD) Hb 
(g/dl) 
8.7(0.5) 8.4(1.4) 8.5(1.0) 9.7(0.8) 9.2(0.6)* 8.8(1.0)* 8.0(1.1) 
Mean (SD) WBC 
count in cells × 
5.7(0.03)* 11.8(2.7)* 12.1(0.09)* 11.1(0.6)* 5.7(0.8)* 5.2(0.8) 4.6(1.5) 
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109/l 
Mean (SD) serum 
creatinine (µmol/l) 
83(15) 93(16) 93(19) 82(18) 72(17)* 100(9) 102(23) 
Mean (SD) serum 
cholesterol 
(mmol/l) 
1.74(0.09)* 1.91(0.07) 1.87(0.05) 1.86(0.04) 2.10(0.45) 1.78(0.17) 1.90(0.16) 
Mean (SD) CD4 
cell count (cells/µl) 
503(18)* 300(66)* 88(23)* 352(136)* 510(105)* 562(78)* 238(192)* 
% on ART 100 100 100 100 83 100 92 
Mean (SD) 
duration on ART 
(Years) 
2.3(0.06) 2.3(1.2) 2(0.08) 2.6(0.5) 2.3(1.2) 2.5(0.5) 2.3(0.9) 
Presenting cardiac symptoms (n)** 
Palpitations 0* 2* 6 2* 2* 1* 30 
SOB 3* 6* 6* 5* 3* 3* 35 
Chest pain 3* 2* 7* 3* 5* 2* 34 
Giddiness 0 0 0 0 0 0 3 
• P<0.05, ** Multiple diagnosis present 
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As shown in Table 2, the echocardiographic diagnoses did not differ 
significantly between men and women, or between patients on ART 
and those not on ART.  
 
A univariate analysis was performed to compare having the different 
echocardiographically determined diagnoses in the HIV-positive patients 
and those without it. The table below gives the results following analysis. 
 
Echocardiographically 
determined diagnoses 
Demographic and clinical 
characteristics 
CAD 
• Lowercholesterol levels (1.74 vs 
1.90mmol/l, p = 0.033)  
• Higher white blood cell (WBC) 
count (5.7 vs 4.6× 109 cells/l, p 
= 0.001). 
• Higher CD4cell counts (503 vs 
238 cells/µl, p <0.000). 
• More likely to present with 
palpitations (p = 0.001), 
breathlessness (p = 0.000), and 
chest pain (p = 0.000), 
Corpulmonale 
• Lower systolic BP (115 vs 120.1 
mmHg, p <0.032)  
• Higher mean resting pulse rate 
(115 vs 81.5 beats/min, p < 
0.000). 
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• Higher white blood cell (WBC) 
count (11.8 vs 4.6× 109 cells/l, p 
= 0.001). 
• Higher CD4 cell counts (300 vs 
238 cells/µl, p <0.000). 
• More likely to present with 
palpitations (p = 0.001), 
breathlessness (p = 0.003), and 
chest pain (p = 0.000), 
Myocarditis 
• Younger (40.8 vs 45.5 years, p 
<0.004) 
• Lower systolic BP (109.4 vs 
120.1 mmHg, p <0.000)  
• Lower diastolic BP (71.2 vs 75.6 
mmHg, p <0.012)  
• Higher mean resting pulse rate 
(116.3 vs 81.5 beats/min, p < 
0.000). 
• Higher white blood cell 
(WBC)count (12.1 vs 4.6× 109 
cells/l, p = 0.000). 
• Lower CD4cell counts (88 vs 
238 cells/µl, p <0.000). 
• More likely to present with 
breathlessness (p = 0.003), and 
chest pain (p = 0.021), 
 
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Pericardial effusion 
• Younger (39.3 vs 45.5 years, p 
<0.040) 
• Higher white blood cell (WBC) 
count (11.1 vs 4.6× 109 cells/l, p 
= 0.000). 
• Higher CD4 cell counts (352 vs 
238 cells/µl, p <0.049). 
• More likely to present with 
palpitations (p = 0.001), 
breathlessness (p = 0.001), and 
chest pain (p = 0.000), 
Systolic Dysfunction 
• Lower diastolic BP (69.7 vs 75.6 
mmHg, p <0.02)  
• Higher haemoglobin level (9.2 vs 
8.0 g/dl, p = 0.002).  
• Higher white blood cell (WBC) 
count (5.7 vs 4.6× 109 cells/l, p = 
0.006). 
• Lower serum creatinine (72 vs 
102µmol/l, p = 0.003) 
• Higher CD4 cell counts (510 vs 
238 cells/µl, p <0.000). 
• More likely to present with 
palpitations (p = 0.001), 
breathlessness (p = 0.000), and 
chest pain (p = 0.002), 
 
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Diastolic  Dysfunction 
• Higher CD4 cell counts (562 vs 
238 cells/µl, p <0.000). 
• More likely to present with 
palpitations (p = 0.000), 
breathlessness (p = 0.000), and 
chest pain (p = 0.000), 
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DISCUSSION 
HIV infection is a pandemic now.  Its incidence and prevalence is 
increasing rapidly. The disease affects all the systems in the body. 
But cardiac involvement in HIV infection is common but not 
clinically appreciated. 
Cardiac involvement in HIV infection is common and occurs quite 
early in disease process. 
Our   study  showed   that   majority   of   patients    with HIV  
infection  had echocardiographic findings  which  were clinically 
significant.  
This  shows that  echocardiography w as  an  essential tool  for 
diagnosis of  subclinical  cardiac  abnormalities and it will  help in 
instituting management  at an earlier stage. 
The subjects in our study resembled a typical HIV cohort.  
In our study 82% of the patents were males and 18% were females.  
Majority of the patients are in the age group 41-50 years and only 
17% of the males and no females above 50 years of age. 
 The male female ratio is 4.5:1. All these findings were consistent 
with the Key findings of HIV Estimations 2012 report by NACO. 
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All the patients presented with symptoms of cardiac disease. 32% of 
the patients were confirmed with cardiac disease based on invasive cardiac 
investigations.  58(45.5%) of the patients had CD4 count less than 200,  
31% had CD4 count between 201-350 and 23.5% had CD4 count more 
than 350.109 patients (91%) were on Anti Retroviral Therapy and 9% are 
not on ART. 
Majority of the patients (40%) had the disease between 1-2 years. 
8% of the males and none of the females had the disease beyond 3 years. 
At presentation most patients were in the WHO HIV clinical stage 3 
(53.5%) followed by stage 4 (33%). 
In our study 82% of male subjects and 5% of the female subjects 
had the habit of smoking. In our study 64% of male subjects and 5% of 
the female subjects had the habit of consuming alcohol. 
The most common echocardiographic diagnosis was  
1) Myocarditis, 
2) Pericardial effusion, 
3) Systolic dysfunction and 
4) Diastolic dysfunction  
each at 7% respectively.   
65.55% of the study subjects were significantly normal. 
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Hiv And Coronary Artery Disease 
In our study HIV patients with CAD presented with Lower 
cholesterol levels, higher white blood cell (WBC) count, higher CD4 cell 
count and symptoms of palpitations, breathlessness and chest pain. 
Traditional risk factors lead to increased coronary artery disease in 
the population.  
HIV infection is independently associated with increased 
cardiovascular risk.  
ART also contributes to risk of coronary artery disease especially in 
patients on protease inhibitors.  
Usually increased cholesterol levels, smoking and decreased CD4 
levels are recognized risk factors for CAD. 
But in our study apart from smoking status other variables are not in 
tune with previous studies which have found increased incidence of heart 
attacks and other cardiovascular events among HIV infected induviduals. 
Hiv And Corpulmonale 
Incidence  of pulmonary hypertension was significant in our study. 
In our study HIV patients with corpulmonale presented with lower 
systolic BP, higher mean resting pulse rate, higher white blood cell (WBC) 
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count, higher CD4 cell counts and symptoms of palpitations, 
breathlessness and chest pain. The association between HIV, corpulmonale 
and pulmonary hypertension is well established. 
Common presentation of our patients with pulmonary hypertension 
was shortness of breath, and in all cases it was  attributed to lung disease. 
 These patients did not had any advanced immunosuppression, in 
other words there was  no relation to the disease stage as reflected by CD4 
count in these patients. 
The majority of our patients presentation was shortness of breath, 
which was actually out of proportion to the physical findings, and the CD4 
count was more than 250cells. we found that there was no single predictor 
of pulmonary hypertension. 
The echocardiographic  picture was dilated right ventricle and 
dilated right atrium with  prominent D-sign on the parasternal short-axis 
view. Main pulmonary artery was also dilated  in most cases. 
The prognosis of these patients isusually poor All the  findings in 
our study in relation to corpulmonale correlate well with  previous research 
studies in this area. 
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HIV and Myocarditis 
DCM is a documented cardiac  abnormality in HIV patients. Patients 
with DCM had more advanced  immunosuppression.  In other words  
dilated cardiomyopathy   in HIV was  associated with advanced 
immunosuppression and  lower CD4 cells. 
Myocarditis and direct HIV invasion of myocardial tissue are the 
most common causes of dilated cardiomyopathy in HIV patients. 
 
In our study  
HIV patients with myocarditis presented with younger age group, 
lower systolic BP, lower diastolic BP, higher mean resting pulse rate, 
higher white blood cell, lower CD4 cell counts and symptoms of 
breathlessness and chest pain. 
 
All the findings in our study in relation to myocarditis 
Correlate well with previous research studies in this area, especially 
the low CD4 count, which is an excellent predictor of the presence of LV 
dysfunction. ART and proper nutrition has reduced the incidence of 
myocarditis. They improve survival and enhance quality of life 
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HIV and Pericardial effusion 
In our study 
It was found  that pericardial effusion was commonly seen in our 
HIV patients, with a pattern  ranging from asymptomatic effusions that are 
mild  to severe pericardialeffusion. 
 Pericardial disease is the most common cardiovascular Presentation 
of  HIV infection  and it was found  to  be independent of CD4 count and 
serum albumin levels. 
As the  incidence of HIV infection is on the rising trend, pericardial 
effusion and its sequential  complications may become a major cardiac 
problem  in future in HIV people. 
Pericardiocentesis is not possible  in most of these patients because 
most of the detected  effusions are small and even when   indicated for the 
relief of tamponade, its diagnostic accuracy  was found  to be low. 
 
In our study 
HIV patients with pericardial effusion presented with younger age 
group, higher white blood cell, higher CD4 cell counts and symptoms of 
palpitations, breathlessness and chest pain. 
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All the findings in our study in relation to pericardial effusion 
correlate well with previous research studies in this area. HIV patients 
have an increased risk for pericardial effusions.  
The development of pericardial effusion predicts a poor prognosis. 
This is because end stage HIV infection usually affects the pericardium 
through malignancies and infections.  
HIV and Systolic Dysfunction 
In HIV patients, studies show that systolic dysfunction is present in 
about one third of the cases in echocardiography studies . There has been a 
significant reduction in myocardial contractility .   
As the disease become more and more severe the myocardial 
dysfunction was found to be more .  
The decrease in systolic function has been found to be the cause of 
increased mortality and morbidity in hiv patients and cardiac failure has 
been found to occur in about 5 percent of cases.  
Hence it is very important to screen for early diagnosis of systolic 
dysfunction to increase the life span of the patients. 
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In our study 
 HIV patients with systolic dysfunction presented with lower 
systolic BP, higher haemoglobin level, higher white blood cell, lower 
serum creatinine, higher CD4 cell counts and symptoms of palpitations, 
breathlessness and chest pain. Usually systolic dysfunction is associated 
with low CD4 count. 
 But in our study it does not tally with previous research studies.  All 
the  findings in our study in relation to systolic dysfunction correlate well 
with previous research studies in this area 
 
HIV and Diastolic Dysfunction 
The prevalence of diastolic dysfunction is found to be 30 percent in 
studies. 
 In HIV patients the ventricles became more and more non 
compliant and ventricular filling defects were noted in echocardiography 
signalling diastolic dysfunction. The dysfunction was found to be more 
severe in patients with advanced disease.  
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In our study  
HIV patients with higher CD4 cell counts and symptoms of 
palpitations, breathlessness and chest pain. Diastolic dysfunction is  
alsoassociated with low CD4 count. Again here it does not tally. 
 Diastolic dysfunction may be the first indication of underlying 
cardiac disease in HIV. All the  findings in our study in relation to diastolic 
dysfunction correlate well with previous research studies in this area.  
Traditional risk factors also contribute to development of Diastolic 
dysfunction. Asymptomatic diastolic dysfunction is common among HIV 
infected individuals. HIV infection and Zidovudine increase the risk of 
cardiac diastolic dysfunction.  
The symptoms of cardiac disease like of palpitations, breathlessness 
and chest pain were considerable in our study subjects.  
 
They could be attributable to pulmonary disorders.  
 
Patients with HIV infection are known to develop multiple 
pulmonary opportunistic  infections. 
 
All the patients with cardiac disease had anaemia. This may be due 
to advanced stage in HIV disease. Cardiac function will also be worsened 
by anaemia. 
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CONCLUSIONS 
 82% of the patents were males and 18% were females 
 
 Majority of the patients are in the age group 41-50 years 
 
 The male female ratio is 4.5:1 
 
 32% of the patients were confirmed with cardiac disease 
 
 45.5% of the patients had CD4 count less than 200 
 
 91% were on Anti Retroviral Therapy 
 
 8% of the males had the disease beyond 3 years 
 
 53.5% of the patients were in the WHO HIV clinical stage 3  
 
 Most common echocardiographic diagnosis was myocarditis, 
pericardial  
effusion, systolic dysfunction and diastolic dysfunction, each at 7% 
respectively 
 
 Smoking status correlated with HIV and coronary artery disease 
 
 Low CD4 count correlated with HIV and myocarditis 
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LIMITATIONS 
• Small sample size 
• Confounding factors like traditional risk factors of cardiac disease 
• Causal relationship cannot be established 
• Other predictors like viral load not studied 
 
SUMMARY 
• Cardiac disorders in HIV infected individuals are common 
• Non-invasive investigations like echocardiography helps in early 
diagnosis of asymptomatic cardiac disease in HIV infected 
individuals 
• ART improves clinical outcomes in HIV infected individuals with 
cardiac disease 
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RECOMMENDATIONS 
• Large prospective studies are needed in order to confirm the 
observation in this study 
 
• Clinicians should be vigilant in addressing known risk 
factors for coronary disease in their patients with HIV infection and 
also should be aware of the various cardiovascular manifestations of 
HIV infection 
 
• CVD risk assessment and reduction measures should be 
implemented effectively especially in HIV infected individuals 
 
• Lifestyle modification, including smoking cessation, increased 
physical activity, weight reduction for those who are overweight 
orobese, and education on healthy dietary practices should form part 
of activities of support groups tending to HIV infected individuals 
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PROFORMA 
S.No./ART No.  
Name    : 
Age/Sex    :  
Occupation   : 
Complaints   : Present /Absent    Duration     Grade 
Chest Pain    : 
Breathlessness  : 
Palpitation    : 
Pedal edema /  
Abdominal distention  : 
Past History   : 
  DM  : Yes / No 
  SHT   : Yes / No  
Personal History   :  
 Smoker   : Yes/ No  
 Alcoholic   : Yes / No 
 Clinical Findings   : 
Stage of Disease   : 
Duration since diagnosis  :Whether on ART   : Yes / No  
INV:  
 CBC : Hb   TC  ESR  Plt count  
 Blood sugar  RBS   FBS   PPBS  
 Urea    Creatinine  
 LFT    T.B.   T.Prot  
    SGOT SGPT  SAP  
 
 Lipid profile  TC  TGL   LDL  HDL 
    VLDL 
 Urine  Alb Sugar  deposits  
 CD4 count   
 ECG 
 CXR – PA  
 ECHO   N/Dilated  
 RA 
 RV 
 LA     EF :  
 LV 
Pulm. Artery  
RV Dys.function   Present / Absent  
LV Dys.Function   Present / Absent  
RWMA   Present /  Absent   Site  
LVH     LVDD   I/II/II/IV  
Effusion    Mild/Mod./severe  
Valves    AV  PV TRPG 
    MV  TV PHT Mild/Mod/Sever  
REPORT: 
ABBREVIATION 
 
 
AIDS  - Acquired immunodeficiency syndrome 
HIV  - Human Immunodeficiency Virus  
ART  - Anti Retroviral Therapy  
PI  - Protease Inhibitors  
SHT  - Systemic Hypertension  
DM  - Diabetes mellitus  
ECG - Electrocardiogram  
DCM  - Dilated cardiomyopathy  
EF  - Ejection Fraction  
PHT - Pulmonary Hypertension  
PE  - Pericardial Effusion  
RA - Right atrium  
RV - Right ventricle  
LA - Left atrium  
LV - Left ventricle  
IVS  - Interventricular septum  
DD - Diastolic Dysfunction  
NCEP - National Cholesterol Eradication Program 
CBC - Complete blood count 
 
  
EBV - Ebstein barr virus  
FBS - Fasting Blood Sugar  
RFT  - Renal function test  
LFT  - Liver function test  
ECHO - Echocardiogram 
CXR               -        Chest x ray 
LVH              -         Left ventricular hypertrophy 
RWMA         -         Regional wall motion abnormality 
TRPG            -         Tricuspid regurgitation peak gradient 
  
  
 CONSENT FORM 
 
 1) I AGREE TO PARTICIPATE IN STUDY 
TITLED”ECHOCARDIOGRAPHIC DIAGNOSIS IN HIV POSITIVE 
PATIENTS” 
2) I CONFIRM THAT I HAVE BEEN TOLD ABOUT THIS 
STUDY IN MY MOTHER TONGUE & HEVE HAD THE 
OPPURTUNITY TO ASK QUESTIONS 
3) I UNDERSTAND THAT MY PARTICIPATION IS 
VOLUNTARY & I MAY REFUSE TO PARTICIPATE AT ANY TIME 
WITHOUT GIVING ANY REASON AND WITHOUT AFFECTING MY 
BENEFITS 
4) I AGREE NOT TO RESTRICT THE USE OF ANY DATD OR 
RESULTS THAT ARISE FROM THE STUDY 
5) I AGREE TO DO ECHOCARDIOGRAM 
  
  
  NAME OF PARTICIPANT:                               SIGN/THUMB PRINT 
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